ARQT

Arcutis Biotherapeutics, Inc.

Healthcare
Biotechnology
$2.99B market cap

Forecast run · Sep 14, 2026Upside rank 1850 of 3,136

Model Signal

ForecastQ Daily Probabilities

28.9%

36.4%

11.9%

Analyst Consensus

Recommendation2.17/5 Buy

Last price$23.89

Price target$38.00

Implied move+59.1%

Analysts12

ForecastQ Portfolios

ARQT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.